Introduction {#sec1}
============

Patients with acute depression manifest a range of negative biases in the processing of emotional information, which are believed to contribute to the aetiology and maintenance of the depressed state (Beck, [@ref1]). For example, compared to healthy controls, depressed patients selectively recall more negative, self-related emotional information in memory tasks (Bradley & Matthews, [@ref5]; Bradley *et al.* [@ref6]) and demonstrate negatively biased perception of key social signals such as emotional facial expressions (Gur *et al.* [@ref10]; Bouhuys *et al.* [@ref4]). Such biases have been associated with aberrant responses across a network of neural areas involved in emotional processing, including an increased response of the amygdala to negative facial expressions in depressed patients compared to matched controls (Sheline *et al.* [@ref28]; Surguladze *et al.* [@ref33]; Suslow *et al.* [@ref34]; Victor *et al.* [@ref36]).

We recently proposed that the therapeutic effect of antidepressant drugs could be mediated by early reversal of these negative emotional biases (Harmer *et al.* [@ref12]). For example, in healthy volunteers, 7 days treatment with the selective serotonin re-uptake inhibitor (SSRI), citalopram, and the selective noradrenaline re-uptake inhibitor, reboxetine, diminished the recognition of negative emotional faces, increased recall of positive self-referential words and attenuated the amygdala response to fearful faces as measured by functional magnetic resonance imaging (fMRI; Harmer *et al.* [@ref15], [@ref13]; Norbury *et al.* [@ref23]). Similarly, studies in depressed patients have shown attenuation of the amygdala response to sad and fearful facial expressions during SSRI treatment (Sheline *et al.* [@ref28]; Fu *et al.* [@ref9]; Victor *et al.* [@ref36]). However, in these latter studies amygdala responses were measured at baseline and then again after 8 weeks of SSRI treatment, by which time the therapeutic response had become established and subjective mood improved. Therefore, it is possible that remediation of negative biases in depressed patients during antidepressant treatment could be a consequence of resolution of depression rather than an early effect of drug treatment. In addition, the absence of a placebo control makes it difficult to exclude changes due to order effects during repeated scanning or non-specific effects of treatment.

Accordingly, the aim of the present study was to assess whether in depressed patients, SSRI treatment would remediate neural changes in emotional bias prior to the onset of clinical antidepressant effect. We used a single scan, between-subjects, placebo-controlled design to exclude order and non-specific effects. We predicted that, compared to placebo, short-term SSRI treatment would attenuate amygdala responses to fearful faces in the absence of clinically important changes in mood ratings.

Materials and method {#sec2}
====================

Participants {#sec2-1}
------------

Altogether, 45 participants with major depression and 18 healthy controls completed the fMRI protocol. Controls were recruited through university volunteer lists and advertising in local newspapers. Depressed patients were recruited from a number of sources including newspaper advertisements (*n* = 35) as well as referral from other clinicians or researchers (*n* = 7). All participants were assessed for the presence of current and past psychiatric disorder with the Structured Clinical Interview for DSM-IV (Spitzer *et al.* [@ref32]). The depressed patients met criteria for a primary diagnosis of major depressive disorder. Exclusion criteria for the study were the following. For depressed patients: suffering from psychosis or substance dependence as defined by DSM-IV; being at clinically significant risk of suicidal behaviour; having contraindications to escitalopram treatment or being treated with psychotropic medication \<3 weeks before the study (5 weeks in the case of fluoxetine). For healthy volunteers: current or past history of Axis I disorder as defined by DSM-IV. For both groups: major somatic or neurological disorders; pregnancy or breast-feeding; contraindications to magnetic resonance imaging or concurrent medication, which could alter emotional processing. All participants were right-handed as assessed by the Edinburgh Handedness Inventory (Oldfield, [@ref24]). The study was approved by Oxford Research Ethics Committee and all participants gave written informed consent. Participants were reimbursed for their time and any other expenses.

Study design and drug treatment {#sec2-2}
-------------------------------

This was a double-blind, placebo-controlled, parallel group study where patients with depression were randomly assigned to receive 10 mg escitalopram or placebo each morning for 7 days. Both groups were then scanned on the seventh day of treatment. Mood and anxiety were assessed using the Beck Depression Inventory (BDI; Beck *et al.* [@ref2]), the Hamilton Depression Ratings Scale (HAMD; Hamilton, [@ref11]) and the Spielberger\'s State-Trait Anxiety Inventory (Spielberger *et al.* [@ref31]) immediately before starting treatment and on the seventh day of placebo/escitalopram. After the scan all patients were offered treatment openly with escitalopram according to usual clinical practice. The healthy controls were scanned without any pre-treatment. Their mood ratings were carried out just before the scan.

### Functional MRI data acquisition {#sec2-2-1}

Functional MRI data were acquired in a total of 63 participants on a 3T Siemens TIM TRIO (Siemens AG, Erlangen, Germany), fitted with a body transmit coil and 12-channel head receive coil, located at the University of Oxford, Centre for Clinical Magnetic Resonance Research. Data were excluded from four participants due to technical difficulties (*n* = 2) and rapid head motion. The remaining 59 subjects \[escitalopram-treated (Esc) = 21, placebo-treated (Pla) = 21 and controls (Con) = 17\] were included in the final analyses.

Functional MRI data were acquired with a voxel resolution of 3 × 3 × 3.5 mm, TR/TE/FA = 2000 ms/28 ms/87^o^. A total of 255 volumes were acquired in an experiment lasting 8.5 min. Field maps were acquired using a dual echo 2D gradient echo sequence with echos at 5.19 and 7.65 ms and a repetition time of 444 ms. Data were acquired on a 64 × 64 × 40 grid, with a voxel resolution of 3 mm isotropic. T~1~-weighted structural images were acquired for subject alignment using a magnetisation prepared rapid acquisition by gradient echo sequence with the following parameters: voxel resolution 0.78 × 0.8 × 0.78 mm on a 208 × 256 × 200 grid, TE/TI/TR = 4.8/1100/2040 ms.

### Functional MRI experimental task {#sec2-2-2}

During fMRI scanning, participants completed a simple gender discrimination task involving the rapid presentation of fearful and happy facial expressions. In this task, nine 30-s blocks of a baseline fixation cross (condition A) were interleaved with eight 30-s blocks of the emotional task \[four blocks of fear (condition B) and four blocks of happy (condition C)\]. During each emotional block, participants viewed 10 emotional faces (five female) all derived from a standard set of pictures of facial affect (Matsumoto & Ekman, [@ref20]). Each face was presented for 100 ms and subjects were asked to report the gender of the face via a MRI compatible key pad. To ensure participants remained focused during the task within block inter-stimulus intervals (ISI) ranged between 2500 and 2900 ms (mean ISI = 2900 ms). To reduce potential carry-over effects, cycles of alternation between conditions were counterbalanced across subjects. Thus, during the course of the 8.5-min experiment, half of the subjects completed the following order: ABACABACABACABACA, the remaining subjects ACABACABACABACABA. Stimuli were presented on a personal computer using E-Prime (version 1.0; Psychology Software Tools Inc., USA) and a cloned projection displayed to participants on an opaque screen located at the head of the scanner bore, which subjects viewed using angled mirrors. Subject responses were made via an MRI-compatible keypad. Stimulus presentation/subject button presses were registered and time-locked to fMRI data using E-Prime. Both accuracy (correct gender discrimination) and reaction times were recorded. Immediately before scanning, all subjects received training with another set of stimuli to ensure they fully understood the requirements of the task. Behavioural data were analysed using a repeated measures analysis of variance (ANOVA) model with group as the between-subjects factor and valence as the within-subjects factor implemented in SPSS v. 15 (SPSS Inc., USA).

### Functional MRI pre-processing and statistical analysis {#sec2-2-3}

Functional MRI data were pre-processed and analysed using FSL, version 4.1.4 (Smith *et al*. [@ref29]) Briefly, motion correction was applied using a rigid body registration to the central volume (Jenkinson *et al.* [@ref17]). Brain matter was segmented from non-brain using a mesh deformation approach (Smith, [@ref30]); Gaussian spatial smoothing was applied with a full-width half-maximum of 5 mm; high pass temporal filtering was applied using a Gaussian-weighted running lines filter, with a 3 dB cut-off of 120 s; susceptibility-related distortions were corrected as far as possible using field-map correction routines (Jenkinson *et al.* [@ref17]).

A general linear model was fitted in pre-whitened data space (to account for autocorrelation in the fMRI residuals; Woolrich *et al.* [@ref38]). Two explanatory variables (plus their temporal derivatives) were modelled: 'fear faces' and 'happy faces'. All explanatory variables were convolved with a default haemodynamic response function (γ function, delay = 6 s, [s.d]{.smallcaps}. = 3 s), and filtered by the same high pass filter as the data. Finally, each subject\'s estimated motion parameters (derived from the motion correction pre-processing step described above) were also included in the model as regressors of no interest. The full model was simultaneously regressed to the data, giving the best-fitting amplitudes for each explanatory variable. Individual subject data were then combined at the group level using a full mixed-effects analysis (Woolrich *et al.* [@ref37]), including gender as covariate of no interest. This mixed-effects approach enables generalisation of the results beyond the sample of subjects tested. At the group level, individual participant \'s first-level difference maps were compared within an amygdala region of interest \[clusters determined by Z \>2.3 and a (corrected) cluster significance threshold of *p* = 0.05\], derived from the Harvard--Oxford anatomical atlas. When a statistically significant interaction was observed in the overall 3 × 2 analysis, this was decomposed by comparing each group to one another for the contrast fearful *versus* happy facial expressions within the amygdala region of interest. If these group (2) × emotion (2) interactions were significant, mean percentage signal change was extracted from the significant functional clusters and compared across groups using independent samples *t* tests (performed using SPSS version 16.0). This small volume correction was also used to identify amygdala responses to face presentations in the healthy controls to compare effects of fearful *versus* happy facial expressions (main effect of emotion condition, see Supplementary material, S1).

Outside our amygdala *a priori* areas of interest, significant activations were identified using cluster-based thresholding of statistical images with a height threshold of Z \>2.3 and a (whole-brain corrected) spatial extent threshold of *p* = 0.05. The results from this analysis are presented in the Supplementary material (S2).

Pulsed arterial spin labelling {#sec2-3}
------------------------------

Pulsed arterial spin labelling (PASL) data were also acquired on a subset of participants (Esc = 20, Pla = 16 and Con = 16). Using a flow-sensitive alternating inversion recovery labelling scheme, whole-brain volumes were acquired with a 3D gradient and spin echo imaging readout (MacIntosh *et al.* [@ref19]). The imaging volume was 200 mm × 200 mm × 120 mm (half *kz*-space coverage; 64 × 64 × 24 matrix size; voxel dimensions: 3.1 mm × 3.1 mm × 5.0 mm). The pulse repetition time and echo time were 3150 ms and 40.6 ms, respectively. Background suppression of static tissue was achieved using two non-selective inversion pulses, prescribed at times that will null the signal from background grey and white matter and that have been shown to improve the temporal stability of the arterial spin labelling measurement. Optimal inversion null times were calculated for signals with T~1~ values of 700 and 1400 ms, which is approximately consistent for white and grey matter, respectively, at 3T (Macintosh *et al.* [@ref19]). A 5 mm full-width half-maximum spatial smoothing kernel filter was applied to the PASL images prior to sinc-interpolated subtraction between tag and control volumes. The top and bottom two slices in each PASL imaging volume were discarded due to wraparound in the z direction. The resulting perfusion maps were smoothed and demeaned prior to inclusion in the between-groups analysis (described above) as voxelwise covariates to minimise the potential impact of these variables on group comparisons.

We also performed a voxelwise between-group whole-brain analysis on resting perfusion images through repeated permutation (5000) of the observed data. Significant activations across the whole brain were identified using cluster-based thresholding of statistical images with a height threshold of *Z* = 2.3 and a (whole-brain corrected) spatial extent threshold of *p* \< 0.05. Finally, amygdala regions of interest (ROIs) were registered to perfusion space to extract mean resting perfusion values (ml/100 g/min) for comparison between-groups.

Results {#sec3}
=======

Demographic data and clinical ratings {#sec3-1}
-------------------------------------

The patients randomized to receive escitalopram or placebo were well matched for age and gender. The Con group had a higher proportion of female participants, but not significantly so (χ^2^ = 2.5, *p* = 0.3; [Table 1](#tab01){ref-type="table"}). HAMD scores indicated that the patients were moderately depressed at baseline and a similar decline in scores was seen in both Esc and Pla groups over the 7 days of treatment ([Table 1](#tab01){ref-type="table"}). Mean (± [s.e.m]{.smallcaps}.) scores in the Esc group fell by 4.4 ± 0.8 *v*. 3.2 ± 1.0 in the placebo group (*t* = 0.86, *p* = 0.4). Similarly, there were no significant difference in decline in scores on the BDI (*t* = 0.64, *p* = 0.5) or state anxiety ratings (*t* = --0.34, *p* = 0.74) between the two groups. Table 1.Demographic and clinical characteristics of participantsVariablePlacebo-treatedEscitalopram-treatedHealthy controls(mean ± [s.d]{.smallcaps}.)(*n* = 21)(*n* = 21)(*n* = 17)Age (years)31.1 ± 12.132.0 ± 10.733.7 ± 12.3Male/Female10/119/124/13Male/Female age31.4 ± 10.4/30.8 ± 4.233.5 ± 11.3/30.8 ± 10.634.4 ± 17.4/33.5 ± 11.2HAMD before treatment (mean ± [s.d]{.smallcaps}.)23.3 ± 4.524.2 ± 5.70.5 ± 0.7HAMD after treatment (mean ± [s.d]{.smallcaps}.)20.0 ± 4.319.8 ± 7.8BDI before treatment (mean ± [s.d]{.smallcaps}.)30.9 ± 9.630.9 ± 9.41.1 ± 1.3BDI after treatment (mean ± [s.d]{.smallcaps}.)23.8 ± 9.5125.4 ± 11.8STAI-S before treatment (mean ± [s.d]{.smallcaps}.)52.4 ± 12.4555.6 ± 11.727.5 ± 5.2STAI-S after treatment (mean ± [s.d]{.smallcaps}.)46.7 ± 10.2350.7 ± 11.2Mean age at onset of depression (range)24 (12--45)23.5 (12--47)Mean number of episodes (range)2.5 (1--10)3 (1--10)Mean months duration of current episode (range)9.5 (1--36)13.4 (1--36)Medication naive (*n*)1110Co-morbidities (number of patients, condition)1 -- somatisation disorder1 -- trichillomania2 -- GAD1 -- social anxiety disorderGender discrimination accuracy % (fear)96.58 ± 5.5496.37 ± 3.8497.35 ± 3.24RT, ms (fear)756.48 ± 130.91725.45 ± 165.81680.44 ± 146.48Gender discrimination accuracy % (happy)97.92 ± 3.3596.62 ± 3.7498.38 ± 1.75RT, ms (happy)760.38 ± 141.17720.96 ± 170.92680.99 ± 164.30[^1]

### Functional MRI behavioural performance {#sec3-1-1}

Due to technical difficulties response accuracy and latency were not acquired for three patients (*n* = 2, Esc). Subsequent analysis, therefore, included 19 Esc, 20 Pla and 17 Con participants. Subjects were highly accurate in their behavioural performance (\>77.5% accuracy). Repeated measures ANOVA revealed no main effect of group or emotion and no group × emotion interaction for either response accuracy or latency (all *F*\'s \<1, see [Table 1](#tab01){ref-type="table"}).

### Functional MRI results {#sec3-1-2}

A two-way repeated-measures ANOVA model in FSL comparing haemodynamic differences across groups \[Esc, Pla and Con and conditions (fear and happy) revealed a significant group × condition interaction in right amygdala ([Fig. 1](#fig01){ref-type="fig"})\]. To decompose this significant interaction, we compared, separately, Pla depressed patients and controls ([Fig. 2](#fig02){ref-type="fig"} *a*), drug treated patients with Pla patients ([Fig. 2](#fig02){ref-type="fig"} *b*) and drug-treated patients with controls within this amygdala region using FSL. These simple main effect analyses revealed greater BOLD response to fear in Pla *vs*. Esc (*t*~40~ = 2.729, *p* = 0.009; [Fig. 2](#fig02){ref-type="fig"} *a*) and Pla *vs*. Con (*t*~28.39~ = 3.51, *p* = 0.001; [Fig. 2](#fig02){ref-type="fig"} *b*). By contrast, the BOLD response to happy faces was similar across groups (all *p*\'s \>0.5). Between-group differences in right amygdala BOLD response were not affected by adding resting perfusion maps as a voxelwise covariate. Similarly, no significant differences were observed in resting brain perfusion either at the whole-brain level or using a ROI-based analysis of the right amygdala (all *p*\'s \>0.2). Fig. 1.Coronal image depicting the group × emotion interaction in right amygdala. The image is thresholded at *Z* = 2.3, *p* \< 0.05 (small volume correction). Lower numeral refers to the coordinate in Montreal Neurological Institute space. Fig. 2.Plot depicting BOLD activation (expressed as % signal change) to fearful and happy facial expressions in right amygdala for (*a*) escitalopram- (Esc) and placebo-treated (Pla) participants, \* *p* = 0.009 and (*b*) for healthy controls (Con) and Pla participants, \*\* *p* = 0.001. Bars show mean, error bars standard error.

Consistent with the prediction that these changes in neural response do not relate to immediate changes in mood or anxiety with antidepressant treatment, there were no significant associations between change in HAMD, BDI and State Anxiety with the response in the amygdala to fear in the Esc group (all *p* values \>0.24).

Discussion {#sec4}
==========

The principal finding of our study is that amygdala response to fearful faces was significantly lower in depressed patients treated with 7 days escitalopram than in those receiving placebo. Ratings of depression or anxiety did not distinguish placebo and drug-treated groups at this point, suggesting that the attenuation in amygdala responsivity was caused by SSRI administration rather than change in clinical state. Consistent with this, there was no association between the change in ratings during treatment and the magnitude of the amygdala response to fearful facial expressions. Further, this effect of SSRI treatment cannot be explained by differences in basal perfusion of the amygdala measured with arterial spin labelling. Finally, the between-subjects placebo controlled design indicates that the differences in amygdala reactivity during SSRI treatment were not due to an effect of repeated fMRI examination or because of non-specific placebo effects.

These findings in SSRI-treated depressed patients are similar to those we noted in a similarly designed, placebo-controlled study of healthy volunteers, where 7 days treatment with the SSRI, citalopram, diminished amygdala responses to fearful facial expressions (Harmer *et al.* [@ref13]). The latter study used backward masking of emotional faces, which were presented below the threshold of conscious awareness. While the emotional stimulus presentations used in the present investigation were not masked, the nature of the task could still be considered 'implicit' and therefore likely to activate limbic regions implicated in rapid automatic appraisal of emotional stimuli (Killgore & Yurgelen-Todd, [@ref18]).

Our findings are also consistent with other studies of antidepressant treatment in depressed patients, which have used fMRI to examine neural responses to fearful and sad faces during more extended periods of SSRI administration. For example, Sheline *et al.* ([@ref28]) found that the amygdala response to masked fearful faces was reduced bilaterally relative to baseline in patients treated with sertraline in doses of approximately 100 mg daily for 8 weeks. Victor *et al.* ([@ref36]), employing a similar treatment regimen, found that sertraline treatment lowered responses to masked sad faces in the right amygdala and Fu *et al.* ([@ref9]) found that 8 weeks fluoxetine treatment (20 mg daily) decreased responses in left amygdala to implicitly presented sad faces of increasing emotional intensity. In these studies, however, most patients had shown clinically significant symptomatic improvement by the time of the second fMRI scan. The neurochemical mechanisms by which SSRIs might lower amygdala responses to fear are not presently clear. The amygdala receives a substantial serotonergic input from the dorsal raphe and, in animals, application of serotonin to amygdala interneurones increases release of γ-aminobutyuric acid, which, in turn, modifies the activity of glutamatergic projection neurones (Rainnie, [@ref26]). Thus, changes in serotonin neurotransmission are well placed to alter the excitability of internal amygdala networks. However, the serotonin receptor subtypes involved and their location with regard to different neuronal types are not fully elucidated.

Taken in conjunction with the above studies, our findings indicate that the attenuating effects of SSRIs on amygdala responses to negative facial expressions in depressed patients can occur early in treatment, prior to meaningful symptomatic improvement. Indeed, in healthy subjects we found that both citalopram (Murphy *et al.* [@ref21]) and the atypical antidepressant, mirtazapine (Rawlings *et al.* [@ref27]), reduced amygdala responses to fear a few hours after administration of single therapeutic dose. The translation of these findings from healthy volunteers to an acutely ill patient group suggests that neuropsychologically relevant, remediating effects of antidepressant treatment on emotional processing may be present very shortly after initiation of treatment in depressed patients. Furthermore, in a behavioural study, we have recently found that a single dose of reboxetine in depressed patients reversed negative emotional biases in both facial expression recognition and emotional memory in the absence of any change in subjective mood (Harmer *et al.* [@ref14]).

In the present study, the effect of escitalopram to lower fear responses relative to placebo was apparent in the right amygdala rather than bilaterally and in our antidepressant studies in healthy volunteers, using the same or similar paradigms, changes in fear processing have been most apparent in the right amygdala (Harmer *et al.* [@ref13]; Murphy *et al.* [@ref21]; Rawlings *et al.* [@ref27]). However, the investigations of antidepressants in depressed patients outlined above do not apparently reveal a consistent pattern in this respect and it is possible that the detection of laterality is influenced by a number of additional factors, such as the nature of the task and the number of trials presented. We also saw here a specific effect of SSRI treatment on response to negative facial expressions, which is the best replicated effect seen early and late in treatment (see Harmer *et al.* [@ref12a]). However, some studies have also revealed increased amygdala responses to happy facial expressions after antidepressant treatment (Norbury *et al.* [@ref22]; Rawlings *et al.* [@ref27]; Victor *et al.* [@ref36]), which were not detected here. The reason for this discrepancy is unclear but could involve differences between drug treatments, patient or volunteer characteristics and explicit *versus* implicit emotional paradigms. Nonetheless, these findings are all in line with a decrease in the relative processing of negative *versus* positive stimuli at the level of the amygdala.

We also studied a group of age-matched healthy controls with the same facial expression task, but it must be noted that control participants did not receive drug or placebo treatment prior to scanning. In addition, there were proportionately more women than men in the Con group than in the patient groups, leading us to enter gender as a covariate in the fMRI analysis (see Method). These differences limit the conclusions that can be drawn from the comparison between the Pla depressed group and healthy volunteer group, although our findings are consistent with a number of other imaging studies that have found increased amygdala responses to negative facial expressions in depressed patients relative to healthy controls (Sheline *et al.* [@ref28]; Surguladze *et al.* [@ref33]; Suslow *et al.* [@ref34]; Victor *et al.* [@ref36]). A major aim of our study was to exclude an effect of repeated scanning and placebo effects in changes in amygdala response in drug-treated patients and we therefore used a single scan, between-subjects placebo-controlled design. However, this approach is open to the objection that the two patient groups may have differed in baseline amygdala reactivity to fearful faces. In as far as we could ascertain, the patients randomised to placebo and escitalopram were similar in terms of personality, clinical and demographic factors, which could have altered the response. However, future studies using a within-subjects design are warranted to explore this question further and to explore whether this early amygdala response is predictive, as hypothesised, of later clinical response.

BOLD magnitude is determined by the interaction between increases in cerebral blood flow, cerebral blood volume and rate of oxygen consumption (Brown *et al.* [@ref7]; Buxton *et al.* [@ref8]) and is affected by differences in resting cerebral blood flow (Brown *et al.* [@ref7]). Characterising the effects of escitalopram (or any drug) upon task-specific brain activity may, therefore, be confounded by drug-related effects on baseline activity. Arguing against this interpretation of our data, we found no significant between-groups differences in resting perfusion using either whole-brain or ROI-based approaches, indicating a degree of region and task specificity unlikely to be related to global effects of escitalopram on baseline blood flow.

An unexpected finding was that the current sample of healthy volunteers did not show increased amygdala response to fearful *versus* happy facial expressions in the statistically significant cluster of interest. However, examination of this within-subjects difference may not be justified in studies where the data derived from the amygdala have been identified through the statistical comparison of depressed and healthy controls. In these circumstances, a difference between response to emotions in the healthy volunteer group may be an artefact of the comparison used to identify the difference between the groups rather than a pattern that will be seen consistently across the whole, or other parts of, the amygdala. Consistent with this, analysis of the amygdala region of interest in healthy volunteers alone revealed a trend for the pattern expected by results in meta-analyses of amygdala responsivity in healthy people \[increased responses to fearful compared to happy facial expressions at *p* = 0.1, see Supplementary material S1 (e.g. Phan *et al.* [@ref25])\].

The apparent rapid resolution of negative emotional processing biases by antidepressant administration in depressed patients supports the notion that such an effect precedes the overt clinical effects of antidepressant treatment and may be a relevant therapeutic mechanism. According to this view, remediation of negative emotional bias is translated into improved subjective mood over time as individuals re-experience and relearn personal and social contingencies in an implicitly transformed emotional world (Harmer *et al.* [@ref12]). If this hypothesis is correct, one might expect that the early changes in emotional bias produced by antidepressant treatment would predict eventual therapeutic outcome. Although, as yet, there are no data exploring this question with functional neuroimaging outcomes measures, behavioural changes in emotional processing with antidepressant drug treatment have been associated with clinical response 4 weeks later (Tranter *et al.* [@ref35]). It is also of great interest that certain negative biases in emotional processing may persist in recovered unmedicated patients who demonstrate abnormalities in behavioural and neural responses similar to those apparent in acute depression (Bhagwagar *et al.* [@ref3]; Victor *et al.* [@ref36]). It would be predicted that such biases should be attenuated by continued antidepressant treatment (Sheline *et al.* [@ref28]; Fu *et al.* [@ref9]; Victor *et al.* [@ref36]). This may provide a mechanism for the established efficacy of antidepressant treatment in longer-term maintenance therapy and a possible means of identifying patients who require it.
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[^1]: HAMD, Hamilton Rating Scale for Depression; BDI, Beck Depression Inventory; STAI-S, State-Trait Anxiety Inventory State; GAD, generalised anxiety disorder; RT, reaction time.
